invoX Pharma
invoX Pharma is a research-driven biopharmaceutical company focused on development, industrialisation and commercialisation of complex respiratory drug-device combination products. The company develops a propellant-free soft-mist inhaler platform and pursues R&D, clinical development and partnering activities for respiratory therapeutics (including small molecules, peptides, biologics and LNP-encapsulated oligonucleotides). invoX operates partnerships for device industrialisation and offers end-to-end supply chain support from development through pilot and commercial supply.
Industries
Nr. of Employees
small (1-50)
invoX Pharma
Patents
Products
Propellant-free soft-mist inhaler platform
A next-generation mechanical inhaler platform that converts water-based liquid formulations into an ultra-fine mist for pulmonary delivery without propellants.
Softhaler
A next-generation, proprietary soft-mist inhalation platform device that uses differentiated technology to deliver propellant-free liquid-based formulations to the lung.
SMI platform technology
A fully industrialised soft-mist inhaler platform technology for life cycle management of existing products, delivering innovative inhalation products with deep lung delivery.
mAb² bispecific antibody technology platform
A technology platform that enables rapid discovery of differentiated drug product candidates and generates tetravalent bispecific antibodies with a natural human antibody format.
Fcab platform
A plug and play clinical stage antibody domain developed by F-star Therapeutics and acquired by invoX, used for developing pioneering new immuno-oncology therapeutics.
Propellant-free soft-mist inhaler platform
A next-generation mechanical inhaler platform that converts water-based liquid formulations into an ultra-fine mist for pulmonary delivery without propellants.
Softhaler
A next-generation, proprietary soft-mist inhalation platform device that uses differentiated technology to deliver propellant-free liquid-based formulations to the lung.
SMI platform technology
A fully industrialised soft-mist inhaler platform technology for life cycle management of existing products, delivering innovative inhalation products with deep lung delivery.
mAb² bispecific antibody technology platform
A technology platform that enables rapid discovery of differentiated drug product candidates and generates tetravalent bispecific antibodies with a natural human antibody format.
Fcab platform
A plug and play clinical stage antibody domain developed by F-star Therapeutics and acquired by invoX, used for developing pioneering new immuno-oncology therapeutics.
Services
Partnered manufacturing of device components and sub-assemblies in dedicated clean-room facilities to support commercialisation.
Flexible supply chain services covering development to pilot and commercial supply, assembly, sterile fill & finish and packaging.
Co-development partnerships leveraging the soft-mist inhaler platform for lifecycle management of approved medicines and innovative programmes.
Regulatory strategy development and quality systems support for combination products and pharmaceutical registrations.
PMO-led programme governance, training and project delivery support for R&D and technical operations.
Partnered manufacturing of device components and sub-assemblies in dedicated clean-room facilities to support commercialisation.
Flexible supply chain services covering development to pilot and commercial supply, assembly, sterile fill & finish and packaging.
Co-development partnerships leveraging the soft-mist inhaler platform for lifecycle management of approved medicines and innovative programmes.
Regulatory strategy development and quality systems support for combination products and pharmaceutical registrations.
PMO-led programme governance, training and project delivery support for R&D and technical operations.
Expertise Areas
- Combination product development (device + formulation)
- Inhalation product engineering and aerosol science
- Respiratory therapeutics R&D
- Manufacturing scale-up and contract device manufacturing
Key Technologies
- Soft-mist inhaler platform (propellant-free aerosol generation)
- Propellant-free liquid-based formulations
- Water-based formulation technologies
- Device component moulding and sub-assembly manufacturing
News & Updates
Announcement of a strategic collaboration with a contract device manufacturer to mould components and produce device sub-assemblies in a dedicated clean room for commercialisation of the soft-mist inhaler platform.
Planned attendance at RDD 2026 (10-14 May 2026, Arizona).
Planned attendance at BIO International Convention (22-25 Jun 2026, San Diego).
Planned attendance at ERS Congress (5-9 Sep 2026, Barcelona).
Planned attendance at CPHI (6-8 Oct 2026, Milan).
Planned attendance at PODD – Partnership Opportunity in Drug Delivery (29-30 Oct 2026, Boston).
Announcement of a strategic collaboration with a contract device manufacturer to mould components and produce device sub-assemblies in a dedicated clean room for commercialisation of the soft-mist inhaler platform.
Planned attendance at RDD 2026 (10-14 May 2026, Arizona).
Planned attendance at BIO International Convention (22-25 Jun 2026, San Diego).
Planned attendance at ERS Congress (5-9 Sep 2026, Barcelona).
Planned attendance at CPHI (6-8 Oct 2026, Milan).
Planned attendance at PODD – Partnership Opportunity in Drug Delivery (29-30 Oct 2026, Boston).